Last reviewed · How we verify
Ergot
At a glance
| Generic name | Ergot |
|---|---|
| Also known as | ergonovine maleate |
| Sponsor | Samuel Lunenfeld Research Institute, Mount Sinai Hospital |
| Target | 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Cluster Headache Prevention
- Cluster headache syndrome
- Migraine
- Vascular headache
Common side effects
- Nausea
- Vomiting
- Paresthesias
- Numbness
- Weakness
- Vertigo
- Localized edema
- Itching
- Transient tachycardia
- Transient bradycardia
- Hypertension
Serious adverse events
- Gangrene
- Ischemia
- Cyanosis
- Absence of pulse
- Cold extremities
- Precordial distress and pain
- EKG changes
- Muscle pains
- Fibrotic complications
Key clinical trials
- Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms (PHASE2)
- Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism (NA)
- A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults (PHASE1)
- Safety and Potency of a High Cabergoline Dosage in Microprolactinomas (PHASE3)
- Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome (PHASE2)
- Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD (NA)
- Nicergoline Use in Dysphagia Patients (PHASE3)
- Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |